TY - JOUR T1 - Osteoid Osteoma: An Updated Review of Epidemiology, Pathogenesis, Clinical Presentation, Radiological Features, and Treatment Option JF - In Vivo JO - In Vivo SP - 1929 LP - 1938 DO - 10.21873/invivo.12459 VL - 35 IS - 4 AU - KOSTAS TEPELENIS AU - GEORGIOS P. SKANDALAKIS AU - GEORGIOS PAPATHANAKOS AU - MARIA ALEXANDRA KEFALA AU - AIKATERINI KITSOULI AU - ALEXANDRA BARBOUTI AU - NIKOLAOS TEPELENIS AU - DIMITRIOS VARVAROUSIS AU - KONSTANTINOS VLACHOS AU - PANAGIOTIS KANAVAROS AU - PANAGIOTIS KITSOULIS Y1 - 2021/07/01 UR - http://iv.iiarjournals.org/content/35/4/1929.abstract N2 - Osteoid osteoma, the third most common benign bone tumor, usually occurs in the cortex of long bones. It consists of a radiolucent nidus surrounded by reactive osteosclerosis. Generally, osteoid osteoma affects young males. Nocturnal pain that eases with salicylates or nonsteroidal anti-inflammatory drugs (NSAID) is the typical clinical presentation. Sometimes, it remains undiagnosed for a long time. Plain radiography and computed tomography are usually sufficient for the diagnosis of osteoid osteoma. Initial treatment includes salicylates and NSAID because the tumor often regresses spontaneously over 2-6 years. Surgical treatment is indicated in case of unresponsive pain to medical therapy, no tolerance of prolonged NSAID therapy due to side effects, and no willingness to activity limitations. Nowadays, minimally invasive techniques have replaced open surgery and are considered the gold standard of surgical treatment. Although cryoablation seems superior in terms of the nerve damage and immunotherapy effect, radiofrequency ablation is the preferred technique. ER -